“Sensorion launched a phase 1b clinical trial end of January 2015 in for a novel vertigo drug”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
sensorion bourse Alternext Paris fr


Sensorion is listed on Alternext Paris:
watch the Bell ceremony
on the 1st day of trading, April 21, 2015

Play video

Sensorion is a biopharmaceutical company committed to finding targeted and innovative treatments for inner ear disease.


Dysfunction or complete loss of function of the vestibular or cochlear system can induce vertigo, imbalance, tinnitus, hearing loss and leads to transient or permanent disability. Unfortunately there are no truly effective, approved and well tolerated treatments available for patients suffering from inner ear pathologies.

Founded in 2009, Sensorion is a French biopharmaceutical company dedicated to the development of targeted and innovative therapies to treat such disorders and fill the currently unmet medical needs.

The company is located in Montpellier (France). At the interface between academic research and industrial development, we adopt a multidisciplinary approach in collaboration with various partners in the ENT field (researchers, clinicians…) to develop new drugs.